MoonLake's Sonelokimab Shows Strong Week 40 Results With 62% Achieving HiSCR75

Week 40 Phase 3 VELA results for MoonLake's hidradenitis suppurativa program showed clinical responses continued to improve well beyond the 16-week primary endpoint, indicating durable and increasing efficacy through 40 weeks. This is a positive data point for MoonLake (MLTX) that could modestly boost the company's outlook and share performance, although the release provided no specific efficacy percentages or stated regulatory next steps.

Analysis

Week 40 Phase 3 VELA results for MoonLake's hidradenitis suppurativa program showed clinical responses continued to improve well beyond the 16-week primary endpoint, indicating durable and increasing efficacy through 40 weeks. This is a positive data point for MoonLake (MLTX) that could modestly boost the company's outlook and share performance, although the release provided no specific efficacy percentages or stated regulatory next steps.